BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

657 related articles for article (PubMed ID: 15994253)

  • 1. Effect of salbutamol on lung function and chest wall volumes at rest and during exercise in COPD.
    Aliverti A; Rodger K; Dellacà RL; Stevenson N; Lo Mauro A; Pedotti A; Calverley PM
    Thorax; 2005 Nov; 60(11):916-24. PubMed ID: 15994253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of operational lung volumes with the use of salbutamol in COPD patients accomplishing upper limbs exercise tests.
    Porto EF; Castro AA; Nascimento O; Oliveira RC; Cardoso F; Jardim JR
    Respir Med; 2009 Feb; 103(2):251-7. PubMed ID: 18930646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of dyspnoea relief and improved exercise endurance after furosemide inhalation in COPD.
    Jensen D; Amjadi K; Harris-McAllister V; Webb KA; O'Donnell DE
    Thorax; 2008 Jul; 63(7):606-13. PubMed ID: 18250181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease.
    Belman MJ; Botnick WC; Shin JW
    Am J Respir Crit Care Med; 1996 Mar; 153(3):967-75. PubMed ID: 8630581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT study.
    Beeh KM; Korn S; Beier J; Jadayel D; Henley M; D'Andrea P; Banerji D
    Respir Med; 2014 Apr; 108(4):584-92. PubMed ID: 24534204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Volume effect and exertional dyspnoea after bronchodilator in patients with COPD with and without expiratory flow limitation at rest.
    Boni E; Corda L; Franchini D; Chiroli P; Damiani GP; Pini L; Grassi V; Tantucci C
    Thorax; 2002 Jun; 57(6):528-32. PubMed ID: 12037229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of bronchodilation on expiratory flow limitation and resting lung mechanics in COPD.
    Dellacà RL; Pompilio PP; Walker PP; Duffy N; Pedotti A; Calverley PM
    Eur Respir J; 2009 Jun; 33(6):1329-37. PubMed ID: 19164347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regional chest wall volumes during exercise in chronic obstructive pulmonary disease.
    Aliverti A; Stevenson N; Dellacà RL; Lo Mauro A; Pedotti A; Calverley PM
    Thorax; 2004 Mar; 59(3):210-6. PubMed ID: 14985554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of salmeterol on respiratory muscle activity during exercise in poorly reversible COPD.
    Man WD; Mustfa N; Nikoletou D; Kaul S; Hart N; Rafferty GF; Donaldson N; Polkey MI; Moxham J
    Thorax; 2004 Jun; 59(6):471-6. PubMed ID: 15170026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of acute bronchodilator reversibility in patients with symptoms of GOLD stage I COPD.
    O'Donnell DE; Laveneziana P; Ora J; Webb KA; Lam YM; Ofir D
    Thorax; 2009 Mar; 64(3):216-23. PubMed ID: 19052054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bronchodilators accelerate the dynamics of muscle O2 delivery and utilisation during exercise in COPD.
    Berton DC; Barbosa PB; Takara LS; Chiappa GR; Siqueira AC; Bravo DM; Ferreira LF; Neder JA
    Thorax; 2010 Jul; 65(7):588-93. PubMed ID: 20627914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pilot study assessing the effect of bronchodilator on dynamic hyperinflation in LAM.
    Baldi BG; de Albuquerque AL; Pimenta SP; Salge JM; Kairalla RA; Carvalho CR
    Respir Med; 2013 Nov; 107(11):1773-80. PubMed ID: 24064347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breathing pattern and chest wall volumes during exercise in patients with cystic fibrosis, pulmonary fibrosis and COPD before and after lung transplantation.
    Wilkens H; Weingard B; Lo Mauro A; Schena E; Pedotti A; Sybrecht GW; Aliverti A
    Thorax; 2010 Sep; 65(9):808-14. PubMed ID: 20805177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of adjunct fluticasone propionate on airway physiology during rest and exercise in COPD.
    Guenette JA; Raghavan N; Harris-McAllister V; Preston ME; Webb KA; O'Donnell DE
    Respir Med; 2011 Dec; 105(12):1836-45. PubMed ID: 21917440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the effects of nebulised and inhaled salbutamol on breathlessness in severe COPD.
    Poole PJ; Saini R; Brodie SM; Black PN
    Respir Med; 2005 Mar; 99(3):372-6. PubMed ID: 15733514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD.
    O'Donnell DE; Sciurba F; Celli B; Mahler DA; Webb KA; Kalberg CJ; Knobil K
    Chest; 2006 Sep; 130(3):647-56. PubMed ID: 16963658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of fluticasone/salmeterol combination on dyspnea and respiratory mechanics in mild-to-moderate COPD.
    Guenette JA; Webb KA; O'Donnell DE
    Respir Med; 2013 May; 107(5):708-16. PubMed ID: 23421968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved respiratory system conductance following bronchodilator predicts reduced exertional dyspnoea.
    Diba C; King GG; Berend N; Salome CM
    Respir Med; 2011 Sep; 105(9):1345-51. PubMed ID: 21482091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease.
    O'Donnell DE; Lam M; Webb KA
    Am J Respir Crit Care Med; 1998 Nov; 158(5 Pt 1):1557-65. PubMed ID: 9817708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of domiciliary nebulizers in managing patients with severe COPD.
    Eiser N; Angus K; McHale S
    Respir Med; 2001 Apr; 95(4):265-74. PubMed ID: 11316108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.